以SLiM为骨髓瘤定义事件的多发性骨髓瘤患者接受自体干细胞移植的结局
该研究纳入30例仅因SLiM标准启动治疗并接受自体干细胞移植(ASCT)的多发性骨髓瘤(MM)患者,与60例以CRAB为骨髓瘤定义事件的匹配队列比较。SLiM组中性粒细胞和血小板植入时间更短,36个月总生存(OS)有延长趋势但未达统计学显著,无进展生存(PFS)两组无差异。作者认为ASCT对仅因SLiM标准移植的MM患者有效且安全,早期干预未带来更深缓解或更好PFS。
要点
- SLiM组中性粒细胞植入中位15天 vs 对照组16天(p=0.049),血小板植入15天 vs 17天(p=0.0004)。
- 36个月OS:SLiM组100% vs 对照组93.27%(95%CI 83.06%-97.42%),SLiM组有延长趋势(p=0.065)。
- 36个月PFS:SLiM组91.61%(95%CI 69.93%-97.87%)vs 对照组65.95%(95%CI 52.31%-76.53%),两组无差异(p=0.414)。
核心结论
- ASCT对仅因SLiM标准接受移植的MM患者有效且安全。
- 对这一无症状队列早期干预似乎未带来更深缓解或更好PFS(与有症状患者相比)。
研究设计与样本
- 研究报告30例仅因SLiM标准启动治疗并接受ASCT的MM患者结局,与60例以CRAB为骨髓瘤定义事件的匹配队列比较。
主要发现
- SLiM组中性粒细胞植入中位时间15天 vs 对照组16天(p=0.049)。
- SLiM组血小板植入中位时间15天 vs 对照组17天(p=0.0004)。
- 36个月OS:SLiM组100% vs 对照组93.27%(95%CI 83.06%-97.42%),SLiM组有延长趋势(p=0.065)。
- 36个月PFS:SLiM组91.61%(95%CI 69.93%-97.87%)vs 对照组65.95%(95%CI 52.31%-76.53%),两组无差异(p=0.414)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2014, the International Myeloma Working Group (IMWG) updated the criteria for diagnosing myeloma and added three additional criteria to the traditional Calcium elevation, Renal impairment, Anemia, Bone disease (CRAB) criteria, called the Sixty % marrow plama cells, Light chain ratio >60, Mri demonstates lytic lesions (SLiM) criteria (clonal bone marrow plasma cells ≥60%, involved to uninvolved free light chain ratio (FLCr) ≥100 and >1 focal lesion on magnetic resonance imaging (MRI)). We report on the outcomes of 30 patients who underwent autologous stem cell transplantation (ASCT) where therapy was initiated solely based on SLiM criteria and compared them to a matched cohort of 60 patients whose myeloma-defining event was CRAB. The SLiM cohort had a shorter median time to neutrophil (15 vs. 16 days, p = 0.049) and platelet (15 vs. 17 days, p = 0.0004) engraftment. The 36-month overall survival (OS) was 100% in the SLiM group and 93.27% in the control group (95% CI 83.06%-97.42%), with a trend towards longer OS in the SLiM cohort (p = 0.065). The 36-month progression-free survival (PFS) was 91.61% in the SLiM (95% CI 69.93%-97.87%) and 65.95% in the control group (95% CI 52.31%-76.53%). There was no difference in the PFS between the cohorts (p = 0.414). ASCT is efficacious and safe in MM patients transplanted only due to SLIM criteria. Early intervention in this asymptomatic cohort did not appear to result in deeper responses or better PFS compared to outcomes in symptomatic patients.
引用
- Vaxman I, Kumar S, Cohen I, et al. Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM. Br J Haematol. 2024. PMID: 39613336. doi:10.1111/bjh.19936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。